Verastem, Inc. (VSTM) is a publicly traded Healthcare sector company. As of October 28, 2026, VSTM trades at $10.07 with a market cap of $1.22B and a P/E ratio of -3.37. VSTM moved -0.33% today. Year to date, VSTM is +39.70%; over the trailing twelve months it is +15.83%. Its 52-week range spans $3.43 to $11.25. Analyst consensus is strong buy with an average price target of $18.17. Rallies surfaces VSTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
VS-7375 tumor shrinkage and higher revenue forecast follow Verastem’s $250 million offering: Verastem said VS-7375 shrank tumors across several advanced pancreatic and colorectal cancers in an early-to-mid-stage trial, and raised its third-quarter net product revenue forecast to $23.9 million-$24.1 million. It plans to start a late-stage pancreatic cancer trial by year-end 2026; the $250 million offering and Michael P. Bailey’s CEO succession were also announced.
| Metric | Value |
|---|---|
| Price | $10.07 |
| Market Cap | $1.22B |
| P/E Ratio | -3.37 |
| EPS | $-2.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.25 |
| 52-Week Low | $3.43 |
| Volume | 4.62K |
| Avg Volume | 0 |
| Revenue (TTM) | $87.53M |
| Net Income | $-202.70M |
| Gross Margin | 0.00% |
7 analysts cover VSTM: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.17.